Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of the drug IMVT-1402 in adults with Graves disease who remain hyperthyroid despite treatment with antithyroid drugs. This randomized, double-blind, placebo-controlled Phase 2b trial aims to compare IMVT-1402 with a placebo by measuring thyroid hormone levels and antithyroid drug doses at 26 weeks. Participants receive IMVT-1402 through weekly injections under the skin at a dose of 600 mg. Different groups receive the drug for either 52 weeks continuously, 26 weeks followed by placebo for 26 weeks, or placebo only for 52 weeks. The study involves a parallel design where participants are assigned to one of these groups randomly. During the study, participants will have their thyroid hormone levels, including T3, FT3, FT4, and TSH, monitored regularly along with their antithyroid drug use. Assessments occur at various time points up to 104 weeks to evaluate thyroid function and antibody levels. Safety and tolerability will also be observed throughout the trial to understand the drugs effects over time.
Actively Recruiting
Researchers are evaluating the effect of olpasiran compared to a placebo on the risk of coronary heart disease death, heart attack, or urgent coronary revascularization in people at risk for a first major cardiovascular event who have elevated lipoproteina levels. This phase 3 study focuses on participants aged 50 to 105 years with multiple cardiovascular risk factors or evidence of atherosclerosis. Participants will be randomly assigned to receive either subcutaneous injections of olpasiran or a placebo. The study is designed as a double-blind, placebo-controlled trial, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period spans up to approximately 6.2 years, during which participants receive regular injections and monitoring. Throughout the study, participants will be assessed for the time until coronary heart disease death, myocardial infarction, or urgent coronary revascularization occurs. Additional measurements include changes in lipoproteina levels and monitoring of cardiovascular events, strokes, and safety through adverse event tracking. Participants will have regular evaluations over the treatment duration, ensuring close follow-up until study completion.